Vyvanse is NOT Appropriate for Bulimia Nervosa
Vyvanse (lisdexamfetamine) should not be used for treating bulimia nervosa in this 29-year-old man who has not responded to fluoxetine 60 mg daily. The 2023 APA guidelines make no recommendation for lisdexamfetamine in bulimia nervosa—it is only suggested (2C) for binge-eating disorder, not bulimia 1.
Why This Matters
The distinction between bulimia nervosa (BN) and binge-eating disorder (BED) is critical here:
- For BN: The APA recommends cognitive-behavioral therapy plus fluoxetine 60 mg daily, either initially or if minimal/no response to psychotherapy alone by 6 weeks 1
- For BED only: Lisdexamfetamine is suggested (2C rating—indicating greater uncertainty) for adults who prefer medication or have not responded to psychotherapy alone 1
The FDA label for Vyvanse does not include bulimia nervosa as an approved indication 2. The FDA label for fluoxetine specifically states that 60 mg/day is the recommended dose for bulimia nervosa, as only this dose was statistically superior to placebo in reducing binge-eating and vomiting frequency 3.
What to Do Instead
For this patient with inadequate response to fluoxetine:
- Verify adequate trial: Ensure the patient has been on fluoxetine 60 mg daily for at least 6-8 weeks with good adherence
- Prioritize psychotherapy: If not already implemented, eating disorder-focused cognitive-behavioral therapy is the cornerstone treatment and should be initiated or intensified 1
- Continue fluoxetine: The guideline recommends fluoxetine alongside CBT, not as monotherapy
- Consider alternative antidepressants: While fluoxetine has the strongest evidence, other SSRIs have been studied if fluoxetine is truly ineffective or not tolerated 4, 5
The Evidence Against Vyvanse for BN
While one small feasibility study (n=18) showed reductions in binge/purge episodes with lisdexamfetamine in BN patients, this was explicitly labeled as preliminary research that "should not be used as evidence for clinicians to prescribe LDX to individuals with BN before its efficacy and safety are properly tested" 6.
Critical safety concerns from this study:
- Mean weight loss of 2.1 kg over 8 weeks
- One participant withdrawn for clinically significant weight loss
- Average heart rate increase of 12.1 bpm
- Long-term safety unknown 6
A 2024 systematic review examining stimulants in eating disorders found insufficient evidence to support their use in BN, with high rates of adverse effects including weight loss, decreased appetite, tachycardia, and cardiovascular changes 7. These effects are particularly concerning in BN patients who may already have electrolyte disturbances and cardiac complications from purging behaviors.
Common Pitfall to Avoid
Do not extrapolate BED data to BN. Though both involve binge eating, bulimia nervosa includes compensatory purging behaviors that create distinct medical risks. Weight loss from stimulants could reinforce restrictive eating patterns and worsen the disorder's trajectory. The purging behaviors in BN also create cardiovascular risks that may be compounded by stimulant-induced tachycardia and blood pressure changes 1.